Maelor plc, the specialist critical care pharmaceuticals and devices

Volplex A 4% solution of succinylated gelatin used in operating theatres and wards in patients who require fluid replacement.
OptiFlo UK brand of a range of catheter irrigation solutions.
ContiSol international brand of a range of catheter irrigation solutions.

Development products

Micelle nanotechnology - A drug delivery system which enables insoluble active pharmaceuticals to be solubilised.
Lead development products in this area relate to:
* Interstitial cystitis and chronic pelvic pain (Plethora Solutions)
* Wound care
* Anaesthesiology

Operational highlights announced 1 June 2006

Licensing agreement with Plethora Solutions plc for micelle nanotechnology drug delivery system for use in the treatment of interstitial cystitis and painful bladder syndrome
Volplex UK rights re-acquired and product re-launched successfully. In-market sales for the second half of the year up 35% compared to the first half compared to the first half
OptiFlo UK in-market sales grow by 32% over the previous year
Jump 17%
http://www.maelor.plc.uk

10 May 2007 - Acquisition of Acorus Therapeutics Ltd completed

24 Feb 2004 - signed a major contract for the distribution of
its plasma substitute product,Volplex, in China. The agreement with Helicon Group
Pty Ltd will lead to Volplex being marketed and distributed in China through a network
of sales offices. Helicon is also charged with the regulatory submission, which should
be completed in 2004.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).

Volplex has expanded its international franchise over the last few months,
gaining regulatory approval in Argentina in December 2003 where it will shortly
be launched. Maelor has established partners in South Africa and Bangladesh
(where regulatory applications have already been submitted) and also in
Australia in preparation for future launches in those markets.

Cannot believe there was not even one trade today !

The stock should be trading higher than 10p given their
strong cash position and long term prospects.

Thinking about going in on this one... now showing signs of recovery ? anyone any news & views?

Bought in this morning at 11.38p... onwards and upwards...no target in mind but would settle for 50% rise in next few months or 100% in a year!

We should ee some interesting annoucements and progress within the next few months. Definately an undervalued find and a serious consideration for any portfolio.

Totally new progressive management team looking to exapnd on MLR's traditional territory

I'm staying in and hoping for the best... might even top up at these levels !

Anyone know what's brewing ? sp is moving up fast-ish...
Now half way back to my breakeven price.

This looks to me like a lunchtime rise, caused by the mm's, due to fall back after 2.00pm

Scotland on Sunday-17Sept
Maelor looks healthy
PERRY GOURLEY

SHARES in healthcare group Maelor, which specialises in drugs and devices for patients in intensive care, appear to be showing signs of moving off the critical list themselves.

Last month they hit an all-time low of under 6p compared to the highs of over 120p seen five years ago.

But since then investors have been told that current trading was encouraging and it was making good progress with its new strategy. Its AGM heard that the board was "looking forward to the future with confidence" and a series of deals by the top men at the company appears to confirm that.

On September 8, chairman Geoff McMillan bought 200,000 at 6.6p and three days later chief executive Tim Wright bought 450,000 shares at 7p. Although the amount spent by the two hardly implies they are putting their houses on the line, they have each significantly increased their holdings. McMillan now holds 500,000 shares and Wright 450,000.

slmchow... good info... thanks... just need a bit of patience with this one to reap the rewards...

Looking good.... from the Sunday Times article...

"I have reinvested the cash, and a bit more, in a tiny healthcare firm called Maelor. This is a turnround play. Historically, Maelor had eggs in too many baskets. But new management came in a year ago, axed an expensive drug project and decided to focus on critical-care products. Only the house broker, Numis, gives it any coverage.

With a market value of only 3m and 1m in cash, there is all to play for. The chief executive, Tim Wright, has done it all before; he built the European operation of the Irish pharma giant, Elan Corporation, from nothing to a business with a 100m turnover. He and other directors bought 1.25m shares in Maelor last month, paying between 6.625p and 8p a share. Coming only three weeks before the company enters its closed period ahead of results when no director can deal that is a positive signal if ever there were one."

Results in about 3 months time

Anyone interested on the report by Lewis Charles Securities on Maelor dated 02/11/06 can go here

http://www.lewischarles.com/

Click on then , accept the legal disclaimer, then scroll down to . The report you want is the only one available at present.

Note: you will have to set your browser to accept pop-ups to be able to access the report.

looks like a nice little earner eh 'enry!

Anyone else in MLR ?

This from yesterday's Peter Shearlocks Small Cap Stock Picks

Transforming deal for Maelor

I tipped critical care products business Maelor last September (at 6.5p) for one reason only: its management had form for building a big pharma business from scratch. That faith appears to have been well placed. Maelor has now achieved a transforming deal with the acquisition of Acorus Therapeutics for up to 13 million. Acorus is in similar areas of neurology and critical care with products that have either been launched on the market or are at a late stage in their development therefore representing low-risk investments.

The deal transforms Maelors profit and loss account. In a trading statement on Thursday it said the final quarter of the year had sustained the upturn noted in the half-year statement and losses would be significantly below expectations. The blood plasma substitute Volplex is clearly still gaining market share. Together with Acorus, which is highly profitable, it looks as if the enlarged Maelor should make a profit of somewhere well over 1 million this year.

To help fund the deal, Maelor placed 80 million new shares at 10p on Thursday, lifting the number of shares in issue to 125 million. With the shares trading at 13.25p after the deal, that puts a value of 16.6 million on the company. There is clearly still a fair amount of upside. Continue to hold. I am a shareholder in Maelor.

After today's EGM I would expect to see some good press over the weekend as this appears to be a star in the making.

Now well in profit after the reverse takeover and with an easily manageable debt and good income flow this should be an interesting, and profitable ride, for the asute punter.

been in for a while now at 11pish so looking fwd to good times

I think that they will soon begin to roll!

Interesting. I am a shareholder in Plethora (PLE), although becoming increasingly disturbed by the failure of the company to produce the big deal for their PE product that was causing so much excitement a while back.

Here's a chart for MLR:

I bought into PLE in October '05 and sold for my Christmas box the same year. I think it has a little further to fall still and its on my watch list.

Meanwhile I expect MLR to rocket no exaggeration I mean rocket. But dont follow me, look at it yourselves.

Just out of interest and for those who have not seem this:-

Maelor plc

Maelor and Plethora Solutions enter into a licensing agreement for micelle nanotechnology
June 1st 2006 - Maelor Pharmaceuticals PLC (Maelor; AIM:MLR), the specialist critical care company, and Plethora Solutions Holdings PLC (Plethora or the Company, AIM : PLE), a UK-based speciality pharmaceutical company, are pleased to announce that Maelor has granted Plethora a licence to Maelors micelle nanotechnology delivery system.

Under the terms of the agreement, Maelor will provide Plethora with a worldwide, exclusive licence to Maelors micelle formulation nanotechnology, for application in Plethoras PSD597 programme for the treatment of interstitial cystitis and painful bladder syndrome (IC/PBS).

Plethora will be responsible for product development and the licence agreement is based upon an upfront payment, development and sales milestones and royalties to Maelor.

Micelle nanotechnology entraps drug compounds inside minute particles built up from polymers. This formulation technique can potentially deliver effective concentrations of drugs which would otherwise be insoluble in aqueous solution. The micelles may also protect the entrapped drug from hydrolysis by enzymes or protect the drug from extreme pH environments and thus enable more drug to be delivered to its site of action.

Plethora has already completed clinical pilot studies which indicated that its proprietary treatment, PSD597, can result in symptomatic relief from IC/PBS. Plethora recently announced that it had initiated a Phase II, double-blind, placebo-controlled clinical study in up to 20 centres in the US and Canada, with preliminary results anticipated at towards the end of 2006. In this study, PSD597 is being delivered locally into the bladder in a procedure conducted in an out-patient clinic. Following successful completion of this study, the micelle technology will be incorporated into the next stage of development and may open up the potential for patients to self administer treatments for interstitial cystitis.
IC/PBS is a condition characterised by chronic pelvic pain and afflicts up to two million women in the United States and Europe. The causes of IC/PBS are unknown and the few available approved treatments fail to bring about immediate and long-lasting symptomatic relief.

Maelor plc

Tim Wright, Chief Executive Officer of Maelor, commented:
As a specialist urology company with expertise in the clinical development of an IC/PBS treatment, Plethora is ideally placed to develop an effective and convenient micelle-based product for this debilitating condition and we are pleased to build upon their proprietary position in this area by providing access to our micelle nanotechnology.

Steven Powell, Chief Executive Officer of Plethora, commented:
Maelors micelle delivery technology is an ideal enhancement for this product, potentially broadening the patient population for this much needed treatment which has unique benefits for IC/PBS sufferer.

Enquiries:
Maelor plc
Tim Wright, CEO Tel: 01978 810153
Financial Dynamics
Ben Atwell/John Gilbert Tel: 020 7831 3113
Plethora Solutions
Steven Powell
Tel : 0207 269 8630
Buchanan Communications
Isabel Podda
Tel : 0207 466 5000

Notes to Editors:
A
bout Maelor:
Maelor plc is a specialist critical care pharmaceuticals and devices company. The company commercialises its critical care portfolio directly in the UK and commercialises early stage technology and non-core products through effective relationships with partners. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:MLR) Further information is available at www.maelor.plc.uk

About Plethora:
Plethora is focused on the development of products for the treatment of urological disease. The Company has products in clinical development for the treatment of overactive bladder, benign prostatic hyperplasia, stress urinary incontinence, interstitial cystitis and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based speciality sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) Further information is available at www.plethorasolutions.co.uk

And this one----
RNS Number:4720U Maelor PLC 05 April 2007

5 April 2007


Maelor plc ("Maelor" or the "Company")
Pre-Close Statement and Trading update


The Board of Maelor plc (AIM:MLR), the specialist critical care company is pleased to announce that it expects the outcome for the full year to 31st March 2007 to be ahead of current market expectations.

The positive trading highlighted at the Company's Interim Results on 2nd November 2006 has been sustained into the last quarter of the financial year and the Board anticipates a significant reduction in losses for the second half of the financial year. The sales growth of Volplex, a plasma substitute product, the commercialisation of which has been taken in-house, has continued, driven by active promotion and successful tendering for regional contracts. Sales of catheter flushing devices also continue to progress well.

The Company is actively building its specialist critical care portfolio having recently further added to its "specials" portfolio a fluid and volume replacement product as well as AquiHex, a product that the Company has developed, for use in hospital infection control. In parallel, late stage development of its complementary plasma substitute product, ISOplex, is progressing to schedule with approval still targeted for late 2008.

Commenting on the Company's performance Tim Wright CEO said:

"We are very pleased with the progress that Maelor has made since the strategic review in June 2006. In line with our new strategy the business is now focused, stabilised and well positioned for rapid organic and acquisitive growth. The acquisition of Acorus announced separately today represents a further step in our strategy to establish a significant business in hospital specialist medicine"


Ends -
For further information, call:

Tim Wright, Maelor plc - 01244 625150

Billy Clegg/Edward Westropp, Financial Dynamics - 020 7831 3113

Matthew Hall, Noble & Company - 020 7763 2200


This information is provided by RNS
The company news service from the London Stock Exchange